Haemonetics
178 hedge funds and large institutions have $1.48B invested in Haemonetics in 2016 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 77 increasing their positions, 49 reducing their positions, and 24 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
57% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 49
33% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 24
4% more funds holding
Funds holding: 171 → 178 (+7)
0.8% less ownership
Funds ownership: 100.83% → 100.03% (-0.8%)
17% less capital invested
Capital invested by funds: $1.79B → $1.48B (-$311M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21.4M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$18.8M |
| 3 |
RCM
Rutabaga Capital Management
Boston,
Massachusetts
|
+$18.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$16.9M |
| 5 |
Renaissance Technologies
New York
|
+$15.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WHG
Westwood Holdings Group
Dallas,
Texas
|
-$75.7M |
| 2 |
CI
Cambiar Investors
Denver,
Colorado
|
-$28.8M |
| 3 |
ACM
American Capital Management
New York
|
-$24.5M |
| 4 |
BCIM
Black Creek Investment Management
Toronto,
Ontario, Canada
|
-$13.8M |
| 5 |
AAM
AMI Asset Management
Los Angeles,
California
|
-$13.2M |
HAE Hedge Fund Activity: Q2 2016 in Review
178 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q2 2016, worth a combined $1.48B — down 17% from $1.79B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new HAE positions and 24 closed out — a net gain of 8 holders — while 77 added to existing stakes and 49 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $21.4M. The largest seller was Westwood Holdings Group, exiting entirely with an estimated $75.7M sold.
- 178 institutional investors held Haemonetics (HAE) as of Q2 2016, up from 171 in Q1 2016.
- Funds reported $1.48B of Haemonetics stock for Q2 2016, down 17% quarter-over-quarter.
- 32 funds opened new Haemonetics positions in Q2 2016 and 24 closed out, a net change of +8 holders.
- The largest Haemonetics buyer in Q2 2016 was T. Rowe Price Associates, an estimated $21.4M added.
- The largest Haemonetics seller in Q2 2016 was Westwood Holdings Group, an estimated $75.7M sold.
Based on aggregated 13F filings for Q2 2016.